Profile of evolocumab and its potential in the treatment of hyperlipidemia
Arrigo FG Cicero, Alessandro Colletti, Claudio Borghi Medical and Surgical Sciences Department, University of Bologna, Bologna, Italy Abstract: Despite the proven efficacy of statins, they often fail to achieve low-density lipoprotein (LDL) cholesterol goals, especially in high-risk patients. More...
Main Authors: | Cicero AF, Colletti A, Borghi C |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-06-01
|
Series: | Drug Design, Development and Therapy |
Online Access: | http://www.dovepress.com/profile-of-evolocumab-and-its-potential-in-the-treatment-of-hyperlipid-peer-reviewed-article-DDDT |
Similar Items
-
Retargeting the management of hypercholesterolemia – focus on evolocumab
by: Colletti A, et al.
Published: (2016-09-01) -
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
by: Blom DJ, et al.
Published: (2016-05-01) -
Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up
by: Dixon DL, et al.
Published: (2017-07-01) -
Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
by: Federica Fogacci, et al.
Published: (2021-08-01) -
Effect of evolocumab on cholesterol synthesis and absorption[S]
by: Matthew Peach, et al.
Published: (2016-12-01)